Karyopharm Therapeutics Inc.KPTIEarnings & Financial Report
Revenue
$37.9M
Gross Profit
N/A
Operating Profit
$-24.4M
Net Profit
$-37.3M
Gross Margin
N/A
Operating Margin
-64.3%
Net Margin
-98.2%
YoY Growth
-11.4%
EPS
$-4.32
Karyopharm Therapeutics Inc. Q2 FY2025 Financial Summary
Karyopharm Therapeutics Inc. reported revenue of $37.9M (down 11.4% YoY) for Q2 FY2025, with a net profit of $-37.3M (down 256.6% YoY) (-98.2% margin).
Key Financial Metrics
| Total Revenue | $37.9M |
|---|---|
| Net Profit | $-37.3M |
| Gross Margin | N/A |
| Operating Margin | -64.3% |
| Report Period | Q2 FY2025 |
Revenue Breakdown
Karyopharm Therapeutics Inc. Q2 FY2025 revenue of $37.9M breaks down across 2 segments, led by Products at $29.7M (78.3% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Products | $29.7M | 78.3% |
| License And Other | $8.2M | 21.7% |
Karyopharm Therapeutics Inc. Revenue by Segment — Quarterly Trend
Karyopharm Therapeutics Inc. revenue by segment across the last 4 reported quarters, showing how each business line (such as Products and License And Other) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Products | $32.1M | $32.0M | $29.7M | $21.1M |
| License And Other | $2.0M | $12.0M | $8.2M | $9.0M |
Karyopharm Therapeutics Inc. Annual Revenue by Year
Karyopharm Therapeutics Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $146.1M).
| Year | Annual Revenue |
|---|---|
| 2025 | $146.1M |
| 2024 | $145.2M |
| 2023 | $146.0M |
| 2022 | $157.1M |
Karyopharm Therapeutics Inc. Quarterly Revenue & Net Profit History
Karyopharm Therapeutics Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $34.1M | +11.6% | $-102.2M | -299.9% |
| Q3 FY2025 | $44.0M | +13.6% | $-33.1M | -75.2% |
| Q2 FY2025 | $37.9M | -11.4% | $-37.3M | -98.2% |
| Q1 FY2025 | $30.0M | -9.4% | $-23.5M | -78.2% |
| Q4 FY2024 | $30.5M | -9.5% | $-30.8M | -100.8% |
| Q3 FY2024 | $38.8M | +7.7% | $-32.1M | -82.7% |
| Q2 FY2024 | $42.8M | +13.9% | $23.8M | 55.6% |
| Q1 FY2024 | $33.1M | -14.4% | $-37.4M | -112.8% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $33.1M | $42.8M | $38.8M | $30.5M | $30.0M | $37.9M | $44.0M | $34.1M |
| YoY Growth | -14.4% | 13.9% | 7.7% | -9.5% | -9.4% | -11.4% | 13.6% | 11.6% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $204.5M | $214.0M | $189.5M | $164.4M | $127.7M | $104.9M | $96.2M | $108.4M |
| Liabilities | $373.4M | $346.1M | $349.1M | $350.4M | $333.6M | $343.8M | $365.5M | $401.3M |
| Equity | $-169.0M | $-132.1M | $-159.6M | $-186.0M | $-205.9M | $-238.9M | $-269.3M | $-292.9M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-43.7M | $-38.5M | $-19.5M | $-25.8M | $-39.0M | $-18.7M | $-5.9M | $-11.8M |